Product Description
Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens.
Mechanisms of Action: IFN Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Maruho
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Communicable Diseases|Sepsis|Fungemia|Rosacea|Cross Infection|Bacteremia
Phase 2: Acne Vulgaris|Rosacea|Warts|Dermatitis, Atopic|Dermatitis, Seborrheic|Carcinoma in Situ|Condylomata Acuminata|Healthy Volunteers
Phase 1: Healthy Volunteers|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-003106-41 | P2 |
Completed |
Dermatitis, Seborrheic |
2020-01-06 |
|
| CLS001-CO-PR-017 | P2 |
Unknown status |
Dermatitis, Seborrheic |
2019-12-01 |
48% |
| 2006-7041-83/hah | P1 |
Withdrawn |
Other |
2018-09-19 |
|
| 2015-002919-15 | P3 |
Completed |
Rosacea |
2018-04-20 |
|
| 2015-002921-20 | P3 |
Completed |
Rosacea |
2018-04-04 |
|
| CLS001-CO-PR-014 | P2 |
Completed |
Dermatitis, Atopic |
2017-12-20 |
|
| 2016-003849-28 | P2 |
Completed |
Dermatitis, Atopic |
2017-12-15 |
|
| 2015-002920-23 | P3 |
Completed |
Rosacea |
2017-09-21 |
|
| Pharmacodynamics of omiganan in patients with usual type vulvar intraepithelial neoplasia | P2 |
Completed |
Unknown |
2017-10-15 |
|
| CLS001-CO-PR-006 | P3 |
Completed |
Rosacea |
2017-07-14 |
29% |
| CLS001-CO-PR-004 | P3 |
Completed |
Rosacea |
2017-07-05 |
29% |
| 2015-005553-13 | P2 |
Completed |
Warts |
2017-05-11 |
|
| CLS001-CO-PR-011 | P2 |
Completed |
Condylomata Acuminata |
2017-03-21 |
|
| 2016-004702-34 | P2 |
Completed |
Healthy Volunteers |
2017-03-09 |
|
| CLS001-CO-PR-015 | P1 |
Completed |
Healthy Volunteers |
2017-03-07 |
|
| CLS001-CO-PR-010 | P2 |
Completed |
Carcinoma in Situ |
2017-03-07 |
|
| CLS001-CO-PR-005 | P3 |
Completed |
Rosacea |
2017-02-27 |
|
| CLS001-CO-PR-009 | P2 |
Completed |
Acne Vulgaris |
2016-08-01 |
|
| Pharmacodynamics of omiganan in patients with atopic dermatitis | P2 |
Completed |
Dermatitis, Atopic |
2015-12-16 |
|
| CLS001-CO-PR-001 | P2 |
Completed |
Rosacea |
2014-03-01 |
|
| 2005-003194-24 | P3 |
Completed |
Unknown |
2008-06-23 |
|
| CPI-226-301 | P3 |
Completed |
Cross Infection|Sepsis |
2008-06-01 |
|
| CPI-226-03 | P3 |
Completed |
Communicable Diseases |
2008-06-01 |
|
| NCT00027248 | P3 |
Completed |
Sepsis|Fungemia|Bacteremia |
None |
|
| A99005 | P2 |
Completed |
Acne Vulgaris |
None |